Fig. 1From: Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in JapanPatient disposition. Demonstration of the patient progression through the study, from enrollment to allocation within a study group. The number of patients included within each stage are shown. Abbreviation: CRF, case report formBack to article page